Cetuximab for treating non-small cell lung cancer

References

• Surveillance, Epidemiology, and End Results (SEER) Program. 2016
   Google Scholar
• American cancer society: non-small cell lung cancer survival rates, by stage. Available from: www.cancer.org
   Google Scholar
• Masters GA, Graham HF, Temin S, et al. Systemic therapy for stage IV non – small-cell lung cancer : American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488-3515.
   Web of Science ®Google Scholar
• Eberhardt WEE. Concurrent chemoradiotherapy in stage III non–small-cell lung cancer: what is the best regimen? J Clin Oncol. 2015;33:532–533.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) non-small cell lung cancer. 2016.Available from: www.nccn.org
   Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2016;384:665–673.
   Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non–small-cell lung cancer. N Engl J Med. 2014;371:1963–1971.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med. 2014;370:1189–1197.
   PubMed Web of Science ®Google Scholar
• Han B, Tjulandin S, Hagiwara K, et al. Determining the prevalence of Egfr mutations in Asian and Russian patients (Pts) with Advanced Non-Small-Cell Lung Cancer (Ansclc) Of Adenocarcinoma (Adc) and Non-Adc Histology: ignite study. Ann Oncol. 2015;26:i29–i30.
   Web of Science ®Google Scholar
• Greenhalgh J, Dwan K, Boland A, et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016;25:CD010383.
   Web of Science ®Google Scholar
• Zhao H, Fan Y, Ma S, et al. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). J Thorac Oncol. 2015;10:655–664.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–529.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2017;16:141–151.
   Web of Science ®Google Scholar
• Reck M, Rabe KF. Precision diagnosis and treatment for advanced non–small-cell lung cancer. N Engl J Med. 2017;377:849–861.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–1846.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823-1833.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Veale D, Ashcroft T, Marsh C, et al. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 1987;55:513–516.
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Sato JD, Le A, et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci. 1983;80:1337–1341.
   PubMed Web of Science ®Google Scholar
• Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984;44:1002 LP– 1007.
   Web of Science ®Google Scholar
• Masui H, Moroyama T, Mendelsohn J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res. 1986;46:5592 LP– 5598.
   Google Scholar
• Schiller JH, Von Pawel J, Schütt P, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2010;5:1977–1985.
   PubMed Web of Science ®Google Scholar
• Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst. 2005;97:1221–1224.
   PubMed Web of Science ®Google Scholar
• Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as fi rst-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16:763–774.
   Google Scholar
• Fan Z, Masui H, Altas I, et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322 LP– 4328.
   Web of Science ®Google Scholar
• Naramura M, Gillies SD, Mendelsohn J, et al. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother. 1993;37:343–349.
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993;85:1327–1333.
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311 LP– 1318.
   Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301–311.
   PubMed Web of Science ®Google Scholar
• Sunada H, Magun BE, Mendelsohn J, et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci. 1986;83:3825–3829.
   PubMed Web of Science ®Google Scholar
• Kimura H, Sakai K, Arao T, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007;98:1275–1280.
   PubMed Web of Science ®Google Scholar
• Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007;13:1552 LP– 1561.
   Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716–3725.
   PubMed Web of Science ®Google Scholar
• Irani V, Guy AJ, Andrew D, et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67:171–182.
   PubMed Web of Science ®Google Scholar
• Monteverde M, Milano G, Strola G, et al. The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients. Crit Rev Oncol Hematol. 2015;95:179–190.
   PubMed Web of Science ®Google Scholar
• Trotta AM, Ottaiano A, Romano C, et al. Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy. Cancer Immunol Res. 2016;4:366–374.
   PubMed Web of Science ®Google Scholar
• Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res. 2011;71:6261 LP– 6269.
   Web of Science ®Google Scholar
• Pozzi C, Cuomo A, Spadoni I, et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat Med. 2016;22:624–631.
   PubMed Web of Science ®Google Scholar
• Rubin EH, Doroshow J, Hidalgo M, et al. A study to assess the pharmacokinetics (PK) of a single infusion of cetuximab (IMC-C225). J Clin Oncol. 2004;22:3084.
   Web of Science ®Google Scholar
• Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti–epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904.
   PubMed Web of Science ®Google Scholar
• Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti–epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:3234–3243.
   PubMed Web of Science ®Google Scholar
• Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Annal Oncol. 2008;19:362–369.
   Google Scholar
• Wong S. Cetuximab : an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther. 2005;27:684–694.
   PubMed Web of Science ®Google Scholar
• Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non – small-cell lung cancer : cancer and leukemia group B trial 30407. J Clin Oncol. 2011;29:3120-3125.
   PubMedGoogle Scholar
• Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non – small-cell lung cancer : RTOG 0324. J Clin Oncol. 2011;29:2312-2318.
   PubMedGoogle Scholar
• Hallqvist A, Wagenius G, Rylander H, et al. Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: satellite—A phase II study from the Swedish Lung Cancer Study Group. Lung Cancer. 2011;71:166–172.
   PubMed Web of Science ®Google Scholar
• Jensen AD, Münter MW, Bischoff HG, et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab. Cancer. 2011;117:2986–2994.
   PubMed Web of Science ®Google Scholar
• Jatoi A, Schild SE, Foster N, et al. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol. 2010;21:2040–2044.
   PubMedGoogle Scholar
• Heuvel MM, Van Den Uyterlinde W, Vincent AD, et al. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma : efficacy and safety outcomes of a randomized, multi-center phase II study investigating. Radiother Oncol. 2014;110:126–131.
   PubMed Web of Science ®Google Scholar
• Dingemans A-M, Bootsma G, van Baardwijk A, et al. A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin – vinorelbine – cetuximab in patients with stage III non-small-cell lung cancer. J Thorac Oncol. 2014;9:710–716.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factoria. Lancet Oncol. 2015;16:187–199.
   PubMed Web of Science ®Google Scholar
• Nieder C, Pawinski A, Dalhaug A, et al. A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiat Oncol. 2012;7:1–7.
   PubMed Web of Science ®Google Scholar
• Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non – small-cell lung cancer. J Clin Oncol. 2005;23:8786–8793.
   PubMed Web of Science ®Google Scholar
• Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non – small-cell lung cancer. J Clin Oncol. 2016;23:9089–9096.
   Google Scholar
• Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non – small-cell lung cancer. J Clin Oncol. 2007;25:5777-5784.
   Web of Science ®Google Scholar
• Schmid-Bindert G, Gebbia V, Mayer F, et al. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer. 2013;81:428–434.
   PubMed Web of Science ®Google Scholar
• Kim ES, Moon J, Herbst RS, et al. Bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non – small-cell lung cancer. J Thorac Oncol. 2013;8:1519–1528.
   PubMed Web of Science ®Google Scholar
• Redman MW, Crowley JJ, Herbst RS, et al. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res. 2012;18:4004 LP– 4012.
   Web of Science ®Google Scholar
• Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non–small-cell lung cancer. J Clin Oncol. 2006;24:5253–5258.
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525–1531.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non – small-cell lung cancer : results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28:911–917.
   PubMed Web of Science ®Google Scholar
• Pujol J, Pirker R, Lynch TJ, et al. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer. 2014;83:211–218.
   PubMed Web of Science ®Google Scholar
• Ibrahim EM, Abouelkhair KM, Al-Masri OA, et al. Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer : a meta-analysis of randomized controlled trials. lung. 2011;189:193–198.
   PubMed Web of Science ®Google Scholar
• Yang Z-Y, Liu L, Mao C, et al. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2014: CD009948.
   Web of Science ®Google Scholar
• Herbst RS, Kelly K, Chansky K, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non – small-cell lung cancer : Southwest Oncology Group Study S0342. J Clin Oncol. 2010;28:4747–4754.
   PubMed Web of Science ®Google Scholar
• Kim ES, Moon J, Herbst RS, et al. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non–small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2017;8:1519–1528.
   Google Scholar
• Herbst R, Redman M, Kim ES, et al. A randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC): SWOG S0819. J Thorac Oncol. 2017;10:S791–S797.
   Web of Science ®Google Scholar
• Heigener DF, Pereira JR, Felip E, et al. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer : randomized non-comparative phase IIIb NEXT trial. Targ Oncol. 2015;10:255–265.
   PubMed Web of Science ®Google Scholar
• Kim ES, Neubauer M, Cohn A, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy : a phase 3, open-label, randomised trial. Lancet Oncol. 2013;14:1326–1336.
   PubMed Web of Science ®Google Scholar
• O’Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011;12:795–805.
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non–small-cell lung cancer. J Clin Oncol. 2010;28:918–927.
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non – small-cell lung cancer : is KRAS a useful marker in selecting patients for epidermal growth factor receptor – targeted therapy? J Clin Oncol. 2010;28:4769–4777.
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Von Pawel J, et al. EGFR expression as a predictor of survival for fi rst-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer : analysis of data from the phase 3. Lancet Oncol. 2012;13:33–42.
   PubMed Web of Science ®Google Scholar
• Lynch T, Bhagavatheeswaran P, Mukhopadhyay P, et al. 9001 ORAL A retrospective subgroup analysis of EGFR immunohistochemistry (IHC) expression by histo-score correlated to outcomes from the BMS099 1st line phase III NSCLC Trial of Cetuximab (Cet) plus carboplatin/taxane. Eur J Cancer. 2017;47:S591–S592.
   Google Scholar
• Hirsch FR, Varella-Garcia M, Bunn PAJ, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–3807.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer. JNCI J Natl Cancer Inst. 2005;97:643–655.
   Web of Science ®Google Scholar
• Varella-Garcia M, Diebold J, Eberhard DA, et al. EGFR fluorescence in situ hybridisation assay : guidelines for application to non-small-cell lung cancer. J Clin Pathol. 2009;62:970–977.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non – small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008;26:3351–3357.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non–small-cell lung cancer to Gefitinib. N Engl J Med. 2005;352:786–792.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to Gefitinib or Erlotinib is associated with a second mutation in the EGFR kinase domain. Plos Med. 2005;2:225–235.
   Web of Science ®Google Scholar
• Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009;119:3000–3010.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Smit EF, Groen HJM, et al. Dual Inhibition of EGFR with Afatinib and Cetuximab in kinase inhibitor – resistant EGFR -mutant lung cancer with and without T790M mutations. Cancer Discov. 2014;4:1036–1045.
   PubMed Web of Science ®Google Scholar
• Neal JW, Heist RS, Fidias P, et al. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol. 2010;5:1855–1858.
   PubMed Web of Science ®Google Scholar
• Jia Y, Yun C, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534:129–132.
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Barlesi F, Waller CF, et al. Cilengitide combined with cetuximab and platinum-based chemotherapy as fi rst-line treatment patients : results of an open-label, randomized, controlled phase II study (CERTO). Ann Oncol. 2015;26:1734–1740.
   PubMed Web of Science ®Google Scholar
• Hanna NH, Dahlberg SE, Kolesar JM, et al. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced Non – small Cell Lung Cancer (NSCLC) patients who will not receive bevacizumab-based therapy : an Eastern cooperative. Cancer. 2015;121:2253–2261.
   Google Scholar
• Pinto C, Barone CA, Girolomoni G. Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy update of the italian expert recommendations. Am J Clin Oncol. 2016;39:407–415.
   Google Scholar
• Cetuximab label, revised 10/2015
   Google Scholar
• Duffour J, Thézenas S, Dereure O, et al. Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study. Eur J Cancer. 2010;46:3169–3174.
   PubMed Web of Science ®Google Scholar
• Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007;357:514–515.
   PubMed Web of Science ®Google Scholar
• Guarino MJ, Schneider CJ, Hosford MA, et al. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14:119–124.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor–associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007;12:610–621.
   PubMed Web of Science ®Google Scholar
• Fojo T, Grady C. How much is life worth: cetuximab, non–small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101:1044–1048.
   PubMed Web of Science ®Google Scholar
• Gyawali B, Prasad V. Same data; different interpretations. J Clin Oncol. 2016;34:3729–3732.
   PubMed Web of Science ®Google Scholar
• Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors : the EGFR fluorescence in situ hybridization assay. Diagn Pathol. 2006;10:1–10.
   Google Scholar
• TCGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525.
   PubMed Web of Science ®Google Scholar
• Singh RR, Patel KP, Routbort MJ, et al. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer. 2014;111:2014–2023.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742.
   PubMed Web of Science ®Google Scholar
• Scheel AH, Ansén S, Schultheis AM, et al. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations. Oncoimmunology. 2016;5:e1131379.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Chen Q, Ayer T, et al. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. JAMA Oncol. 2015;1:1293–1300.
   PubMed Web of Science ®Google Scholar
• Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Ann Oncol. 2017;28:mdx440.050–mdx440.050.
   PubMedGoogle Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929.
   PubMed Web of Science ®Google Scholar
• Besse B, Garrido P, Puente J, et al. MA09.11 efficacy and safety of necitumumab and pembrolizumab combination therapy in stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017;12:S397.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1 LP– pl1.
   Web of Science ®Google Scholar
• Blumenshein et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non small cell lung cancer: RTOG 0324. J Clin Oncol. 2011;29:2312–2318
   Google Scholar